Licogliflozin
Licogliflozin is a pharmaceutical compound that belongs to the class of sodium-glucose co-transporter 2 inhibitors (SGLT2 inhibitors). It is primarily investigated for its potential use in the treatment of type 2 diabetes mellitus, a chronic condition characterized by insulin resistance and high blood sugar levels.
Mechanism of Action[edit | edit source]
Licogliflozin works by inhibiting the SGLT2 protein in the proximal tubules of the kidney. This protein is responsible for the reabsorption of glucose from the urine back into the bloodstream. By blocking SGLT2, licogliflozin reduces glucose reabsorption, leading to increased glucose excretion through urine, thereby lowering blood glucose levels.
Pharmacokinetics[edit | edit source]
Licogliflozin is administered orally and is absorbed in the gastrointestinal tract. It has a bioavailability of approximately 70%. The drug is metabolized primarily in the liver and excreted through both urine and feces. The half-life of licogliflozin is approximately 12 hours, allowing for once-daily dosing.
Clinical Trials[edit | edit source]
Licogliflozin has undergone several clinical trials to evaluate its efficacy and safety in patients with type 2 diabetes. These studies have shown that licogliflozin effectively lowers blood glucose levels and has a favorable safety profile. Common side effects include urinary tract infections and increased urination.
Potential Benefits[edit | edit source]
In addition to its glucose-lowering effects, licogliflozin may offer other benefits such as weight loss and a reduction in blood pressure. These effects are attributed to the loss of calories through glucose excretion and the osmotic diuresis caused by the drug.
Adverse Effects[edit | edit source]
While generally well-tolerated, licogliflozin can cause some adverse effects. The most common are related to its mechanism of action, such as urinary tract infections and genital mycotic infections. Rarely, it may cause ketoacidosis or acute kidney injury.
Regulatory Status[edit | edit source]
As of the latest update, licogliflozin is still under investigation and has not yet received approval from major regulatory bodies such as the Food and Drug Administration (FDA) or the European Medicines Agency (EMA).
Also see[edit | edit source]
- Sodium-glucose co-transporter 2 inhibitors
- Type 2 diabetes mellitus
- Pharmacokinetics
- Clinical trials
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
